Funding for this research was provided by:
National Institute on Drug Abuse (U01DA035511)
Text and Data Mining valid from 2019-11-22
Received: 9 July 2019
Accepted: 8 November 2019
First Online: 22 November 2019
Compliance with ethical standards
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
: SMO has financial and fiduciary interests in InterveXion Therapeutic LLC (Little Rock, AR), a pharmaceutical company. UAMS has licensed intellectual property developed by SMO to InterveXion Therapeutics LLC. MWS is Chief Operating Officer of InterveXion Therapeutics which had a role in the study design, interpretation, and review of the manuscript. CMK, ALS, GFG, and NEG have no conflicts of interest to declare.